{"id":4198,"date":"2021-05-31T11:15:00","date_gmt":"2021-05-31T11:15:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-inkluderar-forsta-patient-i-pharmashell-studie\/"},"modified":"2021-05-31T11:15:00","modified_gmt":"2021-05-31T11:15:00","slug":"nanexa-inkluderar-forsta-patient-i-pharmashell-studie","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-inkluderar-forsta-patient-i-pharmashell-studie\/","title":{"rendered":"Nanexa inkluderar f\u00f6rsta patient i PharmaShell-studie"},"content":{"rendered":"
\n

Nanexa AB (publ) meddelar idag att bolaget inkluderat f\u00f6rsta patienten i sin f\u00f6rsta kliniska studie med PharmaShell. En fas I-studie i Nanexas produktprojekt NEX-18.<\/strong><\/p>\n<\/div>\n

\n

Studien avser att visa att bolagets NEX-18-produkt, en l\u00e5ngtidsverkande formulering av azacitidin (den aktiva substansen i l\u00e4kemedlet Vidaza), ger \u00f6nskad s\u00e4kerhets- och farmakokinetisk profil. I studien studeras tv\u00e5 doser av NEX-18. Den f\u00f6rsta patienten inkluderades vid Karolinska Universitetssjukhuset Huddinge.<\/p>\n

\u201dInklusionen av f\u00f6rsta patienten i studien \u00e4r en mycket stor milstolpe i v\u00e5r utveckling. Patienten i fr\u00e5ga har f\u00e5tt en injektion av NEX-18 och allt gick bra. Jag ser nu fram emot att inkludera fler patienter s\u00e5 att vi kan avsluta studien under tredje kvartalet.\u201d, s\u00e4ger David Westberg, vd p\u00e5 Nanexa.<\/p>\n

NEX-18-produkten utvecklas f\u00f6r att f\u00f6rb\u00e4ttra behandlingen av MDS (Myelodysplastiskt syndrom), en form av hematologisk cancer som framf\u00f6r allt drabbar \u00e4ldre personer. Det g\u00f6rs genom att utnyttja PharmaShell\u00ae-konceptets unika egenskaper f\u00f6r att skapa en dep\u00e5beredning med styrd fris\u00e4ttning. Dagens behandling inneb\u00e4r att injektioner ges p\u00e5 sjukhus sju dagar i rad varje m\u00e5nad och m\u00e5let med NEX-18-projektet \u00e4r att f\u00f6renkla behandlingen genom att endast beh\u00f6va ge en injektion. F\u00f6rutom att kraftigt f\u00f6renkla f\u00f6r patienterna ser bolaget att NEX-18 kommer att ge betydande kostnadsbesparingar j\u00e4mf\u00f6rt med dagens behandling.<\/p>\n

\u201dMed resultaten fr\u00e5n denna studie avser vi att forts\u00e4tta den kliniska utvecklingen med en fas Ib\/II-studie f\u00f6r att n\u00e5 klinisk Proof of Concept. D\u00e4refter \u00e4r m\u00e5let att driva NEX-18 vidare mot kommersialisering tillsammans med licenspartner eller i egen regi beroende p\u00e5 vad som bed\u00f6ms skapa mest v\u00e4rde f\u00f6r Nanexa\u201d, s\u00e4ger David Westberg.
\u00a0<\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa AB \u00e4r ett nanoteknologiskt drug delivery-f\u00f6retag fokuserat p\u00e5 utvecklingen av PharmaShell\u00ae, ett nytt och banbrytande drug delivery-system med stor\u00a0potential inom ett flertal substanstyper och indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae utvecklar Nanexa egna projekt och har samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland\u00a0AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Nanexa inkluderar f\u00f6rsta patient i PharmaShell-studie<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa AB (publ) meddelar idag att bolaget inkluderat f\u00f6rsta patienten i sin f\u00f6rsta kliniska studie med PharmaShell. En fas I-studie i Nanexas produktprojekt NEX-18.<\/p>\n","protected":false},"template":"","class_list":["post-4198","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexa inkluderar f\u00f6rsta patient i PharmaShell-studie - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-inkluderar-forsta-patient-i-pharmashell-studie\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa inkluderar f\u00f6rsta patient i PharmaShell-studie - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB (publ) meddelar idag att bolaget inkluderat f\u00f6rsta patienten i sin f\u00f6rsta kliniska studie med PharmaShell. En fas I-studie i Nanexas produktprojekt NEX-18.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-inkluderar-forsta-patient-i-pharmashell-studie\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-inkluderar-forsta-patient-i-pharmashell-studie\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-inkluderar-forsta-patient-i-pharmashell-studie\\\/\",\"name\":\"Nanexa inkluderar f\u00f6rsta patient i PharmaShell-studie - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2021-05-31T11:15:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-inkluderar-forsta-patient-i-pharmashell-studie\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-inkluderar-forsta-patient-i-pharmashell-studie\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-inkluderar-forsta-patient-i-pharmashell-studie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa inkluderar f\u00f6rsta patient i PharmaShell-studie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa inkluderar f\u00f6rsta patient i PharmaShell-studie - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-inkluderar-forsta-patient-i-pharmashell-studie\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa inkluderar f\u00f6rsta patient i PharmaShell-studie - Nanexa AB","og_description":"Nanexa AB (publ) meddelar idag att bolaget inkluderat f\u00f6rsta patienten i sin f\u00f6rsta kliniska studie med PharmaShell. En fas I-studie i Nanexas produktprojekt NEX-18.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-inkluderar-forsta-patient-i-pharmashell-studie\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-inkluderar-forsta-patient-i-pharmashell-studie\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-inkluderar-forsta-patient-i-pharmashell-studie\/","name":"Nanexa inkluderar f\u00f6rsta patient i PharmaShell-studie - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2021-05-31T11:15:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-inkluderar-forsta-patient-i-pharmashell-studie\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-inkluderar-forsta-patient-i-pharmashell-studie\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-inkluderar-forsta-patient-i-pharmashell-studie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa inkluderar f\u00f6rsta patient i PharmaShell-studie"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/4198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=4198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}